Toxin Induced Mitochondrial Dysfunction and Neurodegeneration

  • Mohammad I. Sabri

Abstract

Several pieces of evidence suggest a relationship between environmental toxin exposure and onset of neurodegenerative diseases. Epidemiological evidence strongly supports the hypothesis that environmental agents cause neurological diseases, but specific chemicals that produce neurodegenerative diseases have not been identified.1,2 The concern about environmental toxins causing neurological dysfunction (e.g., movement disorders, and memory loss) has increased interest in investigating their role in triggering Parkinson’s disease (PD), Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS), however, little is being done to avert the threat from environmental toxins. The magnitude of the threat from toxic chemicals is illustrated by the fact that about 70,000 chemicals are currently used in industry, most of which have not been tested for their neurotoxic properties.3 As a result, thousands of people are exposed to toxic levels of environmental agents every day. While the number of people affected with neurotoxic disorders is unknown, the Health Care Financing Administration of the U.S. Department of Health and Human Services reported that $23 billion were spent in 1980 alone for the care of people with neurological diseases. In many cases, these illnesses were due to accidental exposure to neurotoxicants.4

Keywords

Toxicity Dopamine Respiration Neuropathy Carbon Monoxide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tanner CM. The role of environmental toxins in the etiology of Parkinson’s disease. Trends Neurosci 1984; 12:49-54.Google Scholar
  2. 2.
    Spencer PS, Butterfield PG. Environmental agents and Parkinson’s disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson’s Disease. New York: Marcel Dekker, Inc., 1995: 319–365.Google Scholar
  3. 3.
    National Research Council, Environmental Neurotoxicology. Washington, D.C.: National Academy of Sciences, 1992.Google Scholar
  4. 4.
    Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: A replication and update. Health Care Financing Review 1985; 7: 68–69.Google Scholar
  5. 5.
    Abou-Donia MB, Wilmarth KR, Jensen KF et al. Neurotoxicity resulting from co-exposure to pyridostigmine bromide, DEET, and permethrin: Implications of Gulf War chemical exposures. J Toxicol Env Health 1996; 48: 35–56.Google Scholar
  6. 6.
    Schapira AHV. Mitochondrial disorders. Curr Opin Gen Develop 1993; 3: 457–465.Google Scholar
  7. 7.
    Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neuroepidemiology 1996; 14: 317–335.Google Scholar
  8. 8.
    Langston JW, Ballard P, Tetrud JW et al. Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983; 219: 979–980.PubMedCrossRefGoogle Scholar
  9. 9.
    Kurland LT. Epidemiological investigations of neurological disorders in the Mariana Islands. In: Pemberton J, ed. Epidemiology Reports on Research and Teaching. New York: Oxford University Press, 1963: 219–223.Google Scholar
  10. 10.
    Spencer PS, Nunn PB, Hugon J et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementian linked to a plant excitant neurotoxin. Science 1987; 237:517-522.Google Scholar
  11. 11.
    Lilienfeld DE, Chan E, Ehland J et al. Rising mortality from motoneuron disease in the USA. Lancet 1989; 1: 710–713.PubMedCrossRefGoogle Scholar
  12. 12.
    Tylleskar T. The causation of konzo. Studies on a Paralytic Disease in Africa. Ph.D. Thesis, Uppsala University, 1994.Google Scholar
  13. 13.
    Spencer PS. Lathyrism. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier Science, 1995.Google Scholar
  14. 14.
    Sabri MI, Lystrup B, Roy DN et al. Action of B-N-oxalylamino-L-alanine on mouse brain NADH-dehydrogenase activity. J Neurochem 1995; 65: 1842–1848.Google Scholar
  15. 15.
    Pai KS and Ravindranath VL. BOAA induces selective inhibition of brain mitochondrial enzyme NADH-dehydrogenase. Brain Res 1993; 621: 215–221.Google Scholar
  16. 16.
    Calne DB, Eisen A, McGeer E et al. Alzheimer’s disease, Parkinsons’s disease and motoneuron disease: Abiotrophic interaction between aging and environment. Lancet 1986; 2: 1067–1070.PubMedCrossRefGoogle Scholar
  17. 17.
    Di Monte DA. Mitochondrial DNA and Parkinson’s disease. Neurology 1991; 41: 38–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119–130.PubMedCrossRefGoogle Scholar
  19. 19.
    Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1992; 61: 1175–1212.PubMedCrossRefGoogle Scholar
  20. 20.
    Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trend Neurosci 1993; 16: 125–161.Google Scholar
  21. 21.
    Lees GJ. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 1993; 54: 287–322.Google Scholar
  22. 22.
    Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995; 56: 1151–1171.PubMedCrossRefGoogle Scholar
  23. 23.
    Dawson Jr. R, Beal MF, Bondy SC et al. Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diesases. Toxicol Appl Pharmacol 1995; 1341-17.Google Scholar
  24. 24.
    Erecinska M, Silver IA. ATP and brain function. J Cereb Blood Flow Metab 1989; 9: 2–19.PubMedCrossRefGoogle Scholar
  25. 25.
    Harding AE. Neurological disease and mitochondrial genes. Trend Neurosci 1991; 14: 132–138.PubMedCrossRefGoogle Scholar
  26. 26.
    Schapira AHV, Mann VM, Cooper JM et al. Anatomic and disease specificity of NADH CoQ, reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990; 552142–2145.Google Scholar
  27. 27.
    Beal MF, Brouillet E, Jenkins BG et al. Neurochemical and histologic characterization of striatal excitotxic lesions produced by the mitochondrial toxin 3nitropropionic acid. J Neurosci 1993; 13: 4181–4192.Google Scholar
  28. 28.
    Schulz JB, Beal MF. Mitochondrial dysfunction in movement disorders. Curr Opin Neurol 1994; 7: 333–339.Google Scholar
  29. 29.
    Mizuno Y, Ikebe S-I, Hattori N et al. Role of mitochondria in the etiology and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1995; 1271:265-274.Google Scholar
  30. 30.
    Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996; 67: 2282–2291.PubMedCrossRefGoogle Scholar
  31. 31.
    Schinder AF, Olson EC, Spitzer NC et al. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996; 16: 6125–6133.PubMedGoogle Scholar
  32. 32.
    Javitch JA, D’Amato RJ, Strittmatter SM et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,z,3,6- tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985; 82: 2173–2177.PubMedCrossRefGoogle Scholar
  33. 33.
    Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolie of the neurotoxin, 1- methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985; 36: 2503–2508.Google Scholar
  34. 34.
    Chan P, DeLanney LE, Irwin I et al. Rapid ATP loss caused by 1-methyl-4-phe-nyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991; 57: 348–351.Google Scholar
  35. 35.
    Langston JW. Mechanism of MPTP toxicity: More answers, more questions. Trends Pharmacol Sci 1985; 6: 375–378.Google Scholar
  36. 36.
    Gluck MR, Youngster SK, Ramsay RR et al. Studies on the characterization of the inhibitory mechanism of 4’-alkylated 1-methyl-4-phenylpyridinium and phenyl-pyridine analogues in mitochondria and electron transport particles. J Neurochem 1994; 63: 655–661.Google Scholar
  37. 37.
    Bates TE, Heales SJR, Davies SEC et al. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: Evidence for a primary involvement of energy depletion. J Neurochem 1994; 63: 640–648.Google Scholar
  38. 38.
    Cleeter MWJ, Cooper JM, Schapira AHV. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement. J Neurochem 1992; 58: 786–789.PubMedCrossRefGoogle Scholar
  39. 39.
    Schulz JB, Matthews RT, Mugit MMK et al. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64: 936–939.Google Scholar
  40. 40.
    Przedborski S, Jackson-Lewis V, Yokoyama R et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996; 93: 4565–4571.Google Scholar
  41. 41.
    Turski L, Bressler K, Rettig K-J et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349:414-4i8.Google Scholar
  42. 42.
    Storey E, Hyman BT, Jenkins B et al. 1-methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992; 581975-1978.Google Scholar
  43. 43.
    Turski L, Turski WA. Towards an understanding of the role of glutamate in neurodegenerative disorders: Energy metabolism and neuropathology. Experientia 1993; 49: 1064–1072.Google Scholar
  44. 44.
    Sonsalla PK, Zeevalk GD, Manzino L et al. MK-8o1 Fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem 1992; 581979-1982.Google Scholar
  45. 45.
    Finiels-Marlier F, Marini AM, Williams P et al. The N-methyl-D-aspartate antagonist MK-8o1 fails to protect dopaminergic neurons from 1-methyl-4phenylpyridinium toxicity in vitro. J Neurochem 1993; 60x968–1971.Google Scholar
  46. 46.
    He F, Zhang S, Zhang C, Qian F, Liu X, Lo X. Mycotoxic induced encephalopathy and dystonia in children. In: Volans GN, Sims J, Sullivan FM, Turner P, eds. Basic Science in Toxicology. London: Taylor and Francis, 1990: 596–604.Google Scholar
  47. 47.
    Ludolph AC, He F, Spencer PS et al. 3-nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991; 18:492-498.Google Scholar
  48. 48.
    Gould DH, Gustine DL. Basal ganglia degeneration, myelin alterations, and exzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol Appl Neurobiol 1982; 8:377-393.Google Scholar
  49. 49.
    Hamilton BF, Gould DH. Correlation of morphologic brain lesions with physiologic alteration and blood-brain barrier impairment in 3-nitropropionic acid toxicity in rats. Acta Neuropathol 1987; 74:67-74.Google Scholar
  50. 50.
    Hamilton BF, Gould DH. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: A type of hypoxic (energy deficient) brain damage. Acta Neuropathol 1987; 72: 286–297.Google Scholar
  51. 51.
    Brouillet E, Jenkins BG, Hyman BT et al. Age-dependent vulnerablility of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993; 6o:356-359.Google Scholar
  52. 52.
    Beal MF, Brouillet E, Jenkins B et al. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993; 61x147–115o.Google Scholar
  53. 53.
    Wullner U, Young AB, Penney JB et al. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994; 63: 1772–1781.Google Scholar
  54. 54.
    Koutouzis TK, Borlongan CV, Scorcia T et al. Systemic 3-nitropropionic acid: long term effects on locomotor behavior. Brain Res 1994; 646242-246.Google Scholar
  55. 55.
    Borlongan CV, Koutouzis TK, Randall TS et al. Systemic 3-nitropropionic acid: Behavioral deficits and striatal damage in adult rats. Brain Res Bull 1995; 36549–556.Google Scholar
  56. 56.
    Nishino H, Shimano Y, Kumazaki M et al. Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci Lett 1995; 186: 161–164.PubMedCrossRefGoogle Scholar
  57. 57.
    Allen CN, Marino JL, Meshul CK. Development of 3-nitropropionic acid (3-NPA)induced neuronal degeneration: A silver impregnation study. Neurodegeneration 1994; 3:225-233.Google Scholar
  58. 58.
    Frim DM, Simpson J, Uhler TA et al. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J Neurosci Res 1993; 35452-458.Google Scholar
  59. 59.
    Ludolph AC, He F, Spencer PS et al. 3-Nitropropionic acid-exogenous animal neurotoxic and possible human striatal toxin. Can J Neurol Sci 1991; 18:492-498.Google Scholar
  60. 60.
    Ludolph AC, Seelig M, Ludolph A et al. 3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants. Neurodegeneration 1992; 1: 155–161.Google Scholar
  61. 61.
    Alston TA, Mela L, Bright HJ. 3-Nitropropionate, the toxic substances of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci USA 1977; 74: 3767–3771.Google Scholar
  62. 62.
    Coles CJ, Edmondson DE, Singer TP. Inactivation of succinate dehydrogenase by 3-nitropropionate. J Biol Chem 1979; 254:5161-5167.Google Scholar
  63. 63.
    Zeevalk GD, Derr-Yellin E, Nicklas WJ. NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3nitropropionic acid. J Neurochem 1995; 64: 455–458.Google Scholar
  64. 64.
    Jenkins BG, Brouillet E, Chen Y-CI et al. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996; 16: 450–461.PubMedCrossRefGoogle Scholar
  65. 65.
    Behrens MI, Koh J, Canzoniero LMT et al. 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons. NeuroReport 1995; 6:545-548.Google Scholar
  66. 66.
    Erecinska M, Nelson D. Effects of 3-nitropropionic acid on synaptosomal energy and transmitter metabolism: Relevance to neurodegenerative brain diseases. J Neurochem 1994; 63:1033-141.Google Scholar
  67. 67.
    Hassel B, Sonnewald U. Selective inhibition of the tricarboxylic acid cycle of GABaergic neurons with 3-nitropropionic acid in vivo. J Neurochem 1995; 65: 1184–1191.Google Scholar
  68. 68.
    Simpson JR, Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp Neurol 1993; 121: 57–64.PubMedCrossRefGoogle Scholar
  69. 69.
    Schulz JB, Henshaw DR, Siwek D et al. Involvement of free radicals in excitotoxicity in vivo. J Neurochem 1995; 642239-2247.Google Scholar
  70. 70.
    Beal MF, Ferrante RJ, Henshaw R et al. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J Neurochem 1995; 65: 919–922.Google Scholar
  71. 71.
    Palfi S, Ferrante RJ, Brouillet E et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington’s disease. J Neurosci 1996; 16: 3019–3025.PubMedGoogle Scholar
  72. 72.
    Borlongan CV, Koutouzis TK, Freeman TB et al. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington’s disease. Brain Res 1995; 697: 254–257.Google Scholar
  73. 73.
    Beal MF. Neurochemistry and toxin models in Huntington’s disease. Curr Opin Neurol 1994; 7: 542–547.Google Scholar
  74. 74.
    Schulz JB, Matthews RT, Henshaw DR et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996; 71: 1043–1048.PubMedCrossRefGoogle Scholar
  75. 75.
    Borowitz JL, Kanthasamy AG, Isom GE. Toxicodynamics of cyanide. In: Somani SM, ed. Chemical Warfare Agents. San Diego: Academic Press, Inc., 1992: 209–236.Google Scholar
  76. 76.
    Way JL. Cyanide intoxication and its mechanism of antagonism. Ann Rev Pharmacol Toxicol 1984; 24: 451–481.Google Scholar
  77. 77.
    Carella F, Grassi MP, Savoiardo M et al. Dystonic-Parkinsonian syndrome after cyanide poisoning: clinical and MRI findings. J Neurol Neurosurg Phsych 1988; 51: 1345–1348.CrossRefGoogle Scholar
  78. 78.
    Valenzuela R, Court J, Godoy J. Delayed cyanide-induced dystonin. J Neurol Neurosurg Phsych 1992; 55: 198–199.Google Scholar
  79. 79.
    Rosenberg NL, Myers JA, Martin WRW. Cyanide induced Parkinsonism: clinical, MRI and 6-fluorodopa PET studies. Neurology 1989; 38142-144.Google Scholar
  80. 80.
    Kato T, Kameyama M, Nakamura S et al. Cyanide metabolism in motor neuron disease. Acta Neurol Scan 1985; 72: 151–156.CrossRefGoogle Scholar
  81. 81.
    Persson S-A, Cassal G, Sellstrom A. Acute cyanide intoxication and central transmitter systems. Fund Appl Toxicol 1985; 5: 5150–5159.Google Scholar
  82. 82.
    Cassal G and Persson S-A. Effects of acute lethal cyanide intoxication on central dopaminergic pathways. Pharmacol Toxicol 1992; 7o: 148–151.CrossRefGoogle Scholar
  83. 83.
    Kanthasamy AG, Borowitz JL, Pavlakovic G et al. Dopaminergic neurotoxicity of cyanide: Neurochemial, histological, and behavioral characterization. Toxicol Appl Pharmacol 1994; 126: 156–163.Google Scholar
  84. 84.
    Spencer PS, Ludolph AC, Kisby GE. Are human neurodegenerative disorders linked to environmental chemicals with excitotoxic properties? Ann NY Acad Sci 1992; 648: 154–16o.PubMedCrossRefGoogle Scholar
  85. 85.
    Aitken P, Brartmen D. The effects of cyanide on neural and synaptic function in hippocampal slices. Neurotoxicology 1989; 10:239-248.Google Scholar
  86. 86.
    Novelli A, Reilly JA, Lysko PG et al. Glutamate becomes neurotoxic via the Nmethyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205–212.PubMedCrossRefGoogle Scholar
  87. 87.
    Maduh EV, Johnson JD, Ardelt BK et al. Cyanide-induced neurotoxicity: Mechanism of attenuation by chlorpromazine. Toxicol Appl Pharmacol 1988; 96: 6o - 67.CrossRefGoogle Scholar
  88. 88.
    Patel MN, Yim GKW, Isom GE. Blockade of N-methyl-D-aspartate receptors prevents cyanide-induced neuronal injury in primary hippocampal cultures. Toxicol Appl Pharmacol 1992; 115: 124–129.PubMedCrossRefGoogle Scholar
  89. 89.
    Yang C-W, Isom GE. Metabotropic receptor mediated inositol triphosphate generation: Stimulation by cyanide. Toxicologist 1994; 14: 351.Google Scholar
  90. 90.
    Mills EM, Isom GE. The induction of apoptosis in differentiated PC12 cells by cyanide. Toxicologist 1994; 14: 362.Google Scholar
  91. 91.
    Patel MN, Yim GKW, Isom GE. N-methyl-D-aspartate receptors mediate cyanide-induced cytotoxicity in hippocampal cultures. Neurotoxicology 1993; 1435-4o.Google Scholar
  92. 92.
    Ardelt BK, Borowitz JL, Isom GE. Brain lipid peroxidation and antioxidant protectant mechanisms following acute cyanide intoxication. Toxicology 1989; 56: 147–154.PubMedCrossRefGoogle Scholar
  93. 93.
    Tylleskar T, Banea M, Bikangi N et al. Cassava cyanogens and konzo, and upper motoneuron disease found in Africa. Lancet 1992; 339: 208–211.Google Scholar
  94. 94.
    Rosling H. Molecular anthropology of cassava cyanogenesis. In: Soral BWS, ed. The Impact of Plant Molecular Genetics. Boston: Birhauser, 1996: 315–327.CrossRefGoogle Scholar
  95. 95.
    Swenne I, Eriksson VJ, Christofferssin R. Cyanide detoxification in rats exposed to acetonitrile and fed a low protein diet. Fund Appl Toxicol 1996; 32: 66–71.CrossRefGoogle Scholar
  96. 96.
    Tor-Agbidye J, Agoston T, Lystrup B. Selective inhibition of mitochondrial cytochrome c oxidase (complex IV) by sodium cyanate. J Neurochem 1995; 46: 596.Google Scholar
  97. 97.
    Cammer W. Release of mitochondrial respiratory control by cyanate salts. Biochim Biophys Acta 1982; 697: 343–346.Google Scholar
  98. 98.
    Sabri MI, Tor-Agbidye J, Palmer VS et al. Glutathione and glutathione reductase activity are reduced in rodent brain by sodium cyanate. J Neurochem 1996; 66: 514c.Google Scholar
  99. 99.
    Smith RP, Wilcox DE. Toxicology of selected nitric oxide-donating xenobiotics with particular reference to azide. Crit Rev Toxicol 1994; 24: 355–378.Google Scholar
  100. 100.
    Smith L, Kruszyna H, Smith RP. The effect of methemoglobin on the inhibition of cytochrome c oxidase by cyanide, sulfide or azide. Biochem Pharmacol 1977; 26: 2247.Google Scholar
  101. 101.
    Tor-Agbidye J, Agoston T, Lystrup B et al. Neurobehavioral changes and in vitro and in vivo inhibition of brain mitochondrial cytochrome c oxidase by sodium azide. Toxicologist 1995; 15: 144.Google Scholar
  102. 102.
    Partridge RS, Monroe SM, Parks JK et al. Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. Arch Biochem Biophys 1994; 310: 210–217.Google Scholar
  103. 103.
    Bennet MC, Rose GM. Chronic sodium azide treatment impairs learning of the Morris water maze task. Behav Neural Biol 1992; 58: 72–75.Google Scholar
  104. 104.
    Bennet MC, Diamond DM, Stryker SL. Cytochrome oxidase inhibition: a novel model of Alzheimer’s disease. J Geriatr Psychiatry Neurol 1992; 5:93-101.Google Scholar
  105. 105.
    Smith RP, Louis CA, Kourszyna R. Acute neurotoxicity of sodium azide and nitric oxide. Fund Appl Toxicol 1991; 17: 120–127.CrossRefGoogle Scholar
  106. 106.
    Mettler FA. Choreoathetosis and striopallidonigral necrosis due to sodium azide. Exp Neurol 1972; 34: 291–308.Google Scholar
  107. 107.
    Gosselin RE, Smith RP, Hodge HC. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984: 111–126.Google Scholar
  108. 108.
    Hurst EW. Experimental demyelination of the central nervous system III. Poisoning with potassium cyanide, sodium azide, hydroxylamine, narcotics, carbon monoxide etc, with some considerations of bilateral necrosis occuring in the basal nuclei. Aust J Exp Biol Med Sci 1942; 20: 297.CrossRefGoogle Scholar
  109. 109.
    Brouillet E, Hyman BT, Jenkins BG. Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Exp Neurol 1994; 129: 175–182.PubMedCrossRefGoogle Scholar
  110. 110.
    Jaffe LS. Sources, characteristics and fate of atmospheric carbon monoxide. Ann NY Acad Sci 1970; 174: 76–88.PubMedCrossRefGoogle Scholar
  111. 111.
    Ginsberg MD. Carbon monoxide. In: Spencer PS, Schaumburg HH, eds. Experimental and Clinical Neurotoxicology. Baltimore: Williams and Wilkins, 1980:374-394.Google Scholar
  112. 112.
    Bird ED, Anton AH, Bullock B. The effect of Manganese inhalation on basal ganglia dopamine concentrations in Rhesus monkey. Neurotoxicology 1984; 5:59-66.Google Scholar
  113. 113.
    Donaldson J. Involvement of manganese in physiological and biochemical process: an overview. Neurotoxicology 1984; 5:1-4.Google Scholar
  114. 114.
    Sloot WN, Vander Sluijs-Gelling AJ, Grainsbergen JBP. Selective lesions by manganese and extensive damage by iron after injection into rat striatum or hippocampus. J Neurochem 1994; 62: 205–216.Google Scholar
  115. 115.
    Barbeau A. Manganese and extrapyramidal disorders. Neurotoxicology 1984; 5: 13–36.PubMedGoogle Scholar
  116. 116.
    Yamada M, Ohno S, Okayasu I. Chronic manganese poisoning: a neuropathologic study with determination of manganese distribution in the brain. Acta Neuropathol 1986; 70: 273–278.PubMedCrossRefGoogle Scholar
  117. 117.
    Bernheimer H, Birkmayer W, Hornykiewicz K. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20415-455.Google Scholar
  118. 118.
    Chandra SV, Srivastava RS, Shukla GS. Regional distribution of metals and biogenic amines in the brain of monkeys exposed to manganese. Toxicol Lett 1979; 4: 189–192.Google Scholar
  119. 119.
    Chandra SV, Shukla GS. Concentrations of striatal catecholamine in rats given manganese chloride through drinking water. J Neurochem 1981; 36: 683–687.PubMedCrossRefGoogle Scholar
  120. 120.
    Ali SF, Duhart HM, Newport GD et al. Manganese-induced reactive oxygen species: Comparison between Mn’ and Mn“. Neurodegeneration 1995; 4:329-334.Google Scholar
  121. 121.
    Maynard LS, Cotzias GC. Partition of manganese among organs and intracellular organelles of the rat. J Biol Chem 1955; 214489-495.Google Scholar
  122. 122.
    Brouillet EP, Shanoleu L, McGarvey V. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Neurol 1993; 120: 89–94.PubMedCrossRefGoogle Scholar
  123. 123.
    Chang LW. Pathogenetic mechanisms of the neurotoxicity of methylmercury. In: Prasad KN, Vernadakis A, eds. Mechanisms of Actions of Meurotoxic Substances. New York: Raven Press, 1982: 51–66.Google Scholar
  124. 124.
    Verity MA, Brown WJ, Cheung M. Organic mercurials encephalopathy: In vivo and in vitro effects of methyl mercury on syanptosomal respiration. J Neurochem 1975; 25: 759–766.PubMedCrossRefGoogle Scholar
  125. 125.
    Omata S, Sugano H. Methyl mercury: Effects on protein synthesis in nervous system. In: Blum K, Manzo L, eds. Neurotoxicology. New York: Marcel Dekker, 1985369-384.Google Scholar
  126. 126.
    Foa V. Neurotoxicity of elemental mercury: occupational aspects. In: Blum K, Manzo L, eds. Neurotoxicology. New York: Marcel Dekker, 1985: 323–343.Google Scholar
  127. 127.
    Yoshino Y, Mozai T, Nakao K. Distribution of mercury in the brain and its sub-cellular units in experimental organic mercury poisoning. J Neurochem 1966; 13397-406.Google Scholar
  128. 128.
    Silbergeld EK. Neurochemical and ionic mechanisms of lead neurotoxicity. In: Prasa KN, Vernadakis A, eds. Mechanisms of Actions of Neurotoxic Substances. New York: Raven Press, 1982: 1–23.Google Scholar
  129. 129.
    Bull RJ, Lutkenhoff SD, McCarty GE. Delay in the postnatal increase of cerebral cytochrome concentrations in lead-exposed rats. Neuropharmacol 1979; 18: 93–102.CrossRefGoogle Scholar
  130. 130.
    Spencer PS, Sabri MI, Schaumburg HH et al. Does a defect of energy metabolism in the nerve fiber underlie axonal degeneration in polyneuropathies? Ann Neurol 1979; 5501-507.Google Scholar
  131. 131.
    Davis GC, Williams AC, Markey SP et al. Chronic parkinsonism secondary to intra-venous injections of meperidine analogs. Psychiatry Res 1979; 1:249-254.Google Scholar
  132. 132.
    Langston JW, Irwin I, Langston EB. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984; 225: 1480–1482.PubMedCrossRefGoogle Scholar
  133. 133.
    Parker Jr. WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989; 26:719-723.Google Scholar
  134. 134.
    Schapira AHV, Cooper JM, Dexter D et al. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990; 54: 823–827.Google Scholar
  135. 135.
    Blass JP, Gibson GE. The role of oxidative abnormalities in the pathophysiology of Alzheimer’s disease. Rev Neurol (Paris) 1991; 147: 513–525.Google Scholar
  136. 136.
    Blass JP. Pathophysiology of the Alzheimer’s syndrome. Neurology 1993; 43:525-538.Google Scholar
  137. 137.
    Parker Jr. WD, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology 1990; 4o: 1302–1303.CrossRefGoogle Scholar
  138. 138.
    Parker Jr. WD, Parks J, Filley CM et al. Electron transport chain defects in Alzheimer’s disease brain. Neurology 1994; 44: 1090–1096.Google Scholar
  139. 139.
    Parker Jr. WD, Mahr NJ, Filley CM et al. Reduced platelet cytochrome c oxidase activity in Alzheimer’s Disease. Neurology 1994; 44: 1086–1089.Google Scholar
  140. 140.
    Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer’s Disease. J Neurochem 1994; 63: 2179–2184.PubMedCrossRefGoogle Scholar
  141. 141.
    Parker Jr. WD, Boyson SJ, Luder AS et al. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in Huntington’s disease. Neurology 1990; 4oa231–1234.Google Scholar
  142. 142.
    Davis RE, Miller S, Herrnstadt C et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer’s disease. Proc Natl Acad Sci USA 1997; 944526-4531.Google Scholar
  143. 143.
    Gu M, Gash MT, Mann VM et al. Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol 1996; 39: 385–389.Google Scholar
  144. 144.
    Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science 1992; 256: 628–632.PubMedCrossRefGoogle Scholar
  145. 145.
    Schapira AHV, Holt IJ, Sweeney M et al. Mitochondrial DNA analysis in Parkinson’s disease. Mov Disord 1990; 5: 294–297.Google Scholar
  146. 146.
    Schapira AHV, Warner T, Gash MT. Complex I functions in familial and spradic dystonia. Ann Neurol 1997; 41: 556–559.Google Scholar
  147. 147.
    Olney JW. Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate. Science 1969; 164: 719–721.PubMedCrossRefGoogle Scholar
  148. 148.
    Only JW. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 1989; 26: 505–525.CrossRefGoogle Scholar
  149. 149.
    Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: Attenuation by NMDA. J Neurosci 1988; 8: 185–196.PubMedGoogle Scholar
  150. 150.
    Choi DW. Calcium: Still center-stage in hypoxicischemic neuronal death. Trends Neurosci 1995; 18: 58–60.Google Scholar
  151. 151.
    Henneberry RC, Novelli A, Cox JA et al. Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. Ann NY Acad Sci 1989; 568:225-233.Google Scholar
  152. 152.
    Zeevalk GD, Nicklas WJ. Chemically induced hypoglycemia and anoxia: Relationship to glutamate receptor-mediated toxicity in retina. J Pharmacol Exp Ther 1990; 253: 1285–1292.PubMedGoogle Scholar
  153. 153.
    Ames BN. The causes of aging and cancer: The misinterpretation of animal cancer tests. Human and Ecological Risk Assessment 1996; 2: 6–9.CrossRefGoogle Scholar
  154. 154.
    Schapira AHV. Oxidative stress in Parkinson’s disease. Neuropathol Appl Neurobiol 1995; 213-9.Google Scholar
  155. 155.
    Schulz JB, Huang PL, Matthews RT et al. Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. J Neurochem 1996; 67430-433•Google Scholar
  156. 156.
    Greene JG, Greenamyre JT. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 1995; 64: 430–436.PubMedCrossRefGoogle Scholar
  157. 157.
    Beal MF, Henshaw DR, Jenkins BG et al. Coenzyme Q,0 and nicotinamide blocked striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994; 36: 882–888.Google Scholar
  158. 158.
    Browne SE, Bowling AC, MacGarvey V. Oxidative damage and metabolic dysfunction in Huntington’s disease: Selective vulnerability of the basal ganglia. Ann Neurol 1997; 41:646–653.Google Scholar
  159. 159.
    Koroshetz WJ, Jenkins BG, Rosen BR et al. Energy metabolism defects in Huntington’s Disease and effects of coenzyme Q. Ann Neurol 1997; 41: 160–165.Google Scholar
  160. 160.
    Shaw CM, Papayannopoulou T, Stamàtoyannopoulos G. Neuropathology of cyan-ate toxicity in thesus monkeys. Pharmacology 1974; 12: 166–176.PubMedCrossRefGoogle Scholar
  161. 161.
    Sabri MI. Assessement of neurotoxicity via chemical perturbation of axonal transport. In: Chang LW, Slikker W Jr, eds. Neurotoxicology, Approaches and Methods. San Diego: Academic Press, 1995: 465–481.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Mohammad I. Sabri

There are no affiliations available

Personalised recommendations